NextCure, Inc. - Common Stock (NQ:NXTC)

5.100 +0.010 (+0.20%)

Delayed Quote Updated: 12:43 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NextCure, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

November 12, 2025

From NextCure

Via GlobeNewswire

NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

November 05, 2025

From NextCure

Via GlobeNewswire

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

October 16, 2025

From NextCure

Via GlobeNewswire

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 04, 2025

From NextCure

Via GlobeNewswire

NextCure (NXTC) Q2 Loss Widens 71% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

August 07, 2025

From NextCure

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 25, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 25, 2025

Via Benzinga

US Stocks Likely To Open On A Mixed Note: Intel, Philips 66, Centene, Charter Earnings In Focus ↗

July 25, 2025

U.S. stock futures swung between gains and losses on Friday after ending on a mixed note on Thursday. Futures were mixed.

Via Benzinga

Why Deckers Outdoor Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket ↗

July 25, 2025

Via Benzinga

NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment ↗

July 24, 2025

NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility.

Via Stocktwits

Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease ↗

July 24, 2025

NextCure Inc. (NASDAQ: NXTC) surged by 44.87% in after-hours trading on Thursday, following presentation of new preclinical data for NC605.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 24, 2025

Via Benzinga

Thursday's after hours session: top gainers and losers ↗

July 24, 2025

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

July 24, 2025

From NextCure

Via GlobeNewswire

Monday's session: top gainers and losers ↗

June 16, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 16, 2025

Via Benzinga

NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline ↗

June 16, 2025

The newly announced partnership aims to develop SIM0505, a novel antibody-drug conjugate developed by Simcere Zaiming for the treatment of solid tumors.

Via Stocktwits

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

June 16, 2025

From NextCure

Via GlobeNewswire

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

May 29, 2025

From NextCure

Via GlobeNewswire

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

May 01, 2025

From NextCure

Via GlobeNewswire

Stay updated with the stocks that are on the move in today's pre-market session. ↗

April 24, 2025

Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 09, 2025

Via Benzinga

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

April 04, 2025

From NextCure

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 19, 2025

Via Benzinga

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

March 06, 2025

From NextCure

Via GlobeNewswire

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe ↗

February 12, 2025

Via Stocktwits

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 24, 2025

Via Benzinga

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

January 10, 2025

From NextCure

Via GlobeNewswire

NextCure Announces Acceptance of IND Application for LNCB74

December 10, 2024

LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences

From NextCure

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.